Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Core Insights - Vor Biopharma Inc. has appointed Andrew Levin, M.D., Ph.D., and Wouter Joustra to its Board of Directors, following a $150 million PIPE financing [1][2] Group 1: Board Appointments - Andrew Levin brings extensive experience in life sciences investment and strategic oversight, previously held by Sarah Reed, who resigned [2][4] - Wouter Joustra is responsible for fund management and has served on boards of several high-growth biotech companies [4][5] Group 2: Company Focus and Development - Vor Biopharma is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development to address serious autoantibody-driven conditions [6] - The company aims to drive long-term shareholder value while focusing on disciplined capital allocation [2][3]